In the early stage of postmenopausal osteoporosis, a decrease in estrogen levels results in increased osteoclastogenesis, which perturbs bone remodeling by accelerating bone loss and subsequently leads to a rapid decrease in bone mineral density.4,46,47 Given that MEF2C positively regulates osteoclastogenesis, SNPs in the MEF2C locus can be associated with changes in osteoclast activity that contribute to the pathogenesis of postmenopausal osteoporosis, which requires further investigation. The gene discussed is MEF2C; the disease is postmenopausal osteoporosis.